Israel’s Avraham Pharmaceuticals announced successful interim results in a Phase 2b clinical trial of ladostigil, for the treatment of mild cognitive impairment (MCI). Fewer MCI patients using ladostigil for 2 years progressed to Alzheimer’s than those using the placebo.

http://www.avphar.com/avraham-pharmaceuticals-announces-successful-second-interim-results-in-phase-2b-study-of-ladostigil-for-the-treatment-of-mild-cognitive-impairment/